Diagnostic Center | May 02, 2024
Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases